You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The platform is designed to isolate exosomes from blood, then release their extracellular RNA cargo for analysis as biomarkers for diseases including cancer.
The drug developer said that the biomarker panel will form the basis of a planned point-of-care test for acute respiratory distress syndrome.
The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.
The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
For the Evry, France-based company, the grant will support its vision of making its technology available as a platform for running oncology assays.
The funding will be used to run a study of breath-based biomarkers and measures of small airway function to enable the definitive diagnosis of asthma.
The Army previously awarded Abbott $11.3 million to develop a TBI test. Abbott has worked with DoD since 2014 to develop tests to help evaluate potential concussions.
The Polish company recently received 9 million Polish złoty ($2.4 million) from the country's National Center for Research and Development to support its activities.
The firm said that it will use the Horizon 2020 Phase II grant to fund a multicenter trial aimed at validating its platform for early detection of recurrent renal cell carcinoma.
Researchers at the University of Birmingham in the UK were awarded £275,000 to develop the new test to measure PSA levels better than conventional tests.